Diabetes Focused Alinea Pharmaceuticals Inks $45 Million Series A

10/11/2005. Alinea Pharmaceuticals Inc., a newly formed clinical stage start-up focused on the treatment of diabetes and metabolic disorders, has secured a $45 million Series A round, according to MPM Capital Venture Partner Todd Foley, a director at the company.

MORE ON THIS TOPIC